Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
PLK Inhibitor
PLK1-IN-9 is a potent inhibitor of polo-like kinase 1 (PLK1) that shows effective inhibition of modified PLK proteins, specifically 1010pT, cdc25c, and PBIP, with IC50 values of 1.6, 0.8, and 1.4 μM, respectively. This compound exhibits significant antiproliferative effects on various cancer cell lines, including HeLa, HL60, SNU387/499, and HepG2, where it induces cytotoxicity and apoptosis. In vivo studies demonstrate that PLK1-IN-9 effectively inhibits tumor growth in a HepG2 xenograft mouse model, highlighting its potential for cancer research applications. -
PLK1 Inhibitor
CD 10899 is a potent Polo-like kinase 1 (PLK1) inhibitor, exhibiting an IC50 of 6 nM. As a hydroxylated metabolite of Volasertib, CD 10899 demonstrates significant pharmacological activity against PLK1, an important target in cancer research. This compound is valuable for studies exploring PLK1's role in cell cycle regulation and tumor progression, making it a useful tool for cancer-related investigations. -
RAD51-BRCA2 Inhibitor
Homologous recombination-IN-1 is an inhibitor of the RAD51-BRCA2 protein-protein interaction, demonstrating an EC50 of 19 μM. This compound effectively disrupts homologous recombination processes, making it a valuable tool for studying DNA repair mechanisms and the underlying biology of cancer. Researchers can utilize Homologous recombination-IN-1 to investigate the roles of RAD51 and BRCA2 in genetic stability and therapeutic responses. -
RAD51 Inhibitor
RAD51-IN-1 is a selective inhibitor of the RAD51 protein, which is crucial for homologous recombination and DNA repair processes. This compound has demonstrated significant anti-tumor activity and may be utilized in cancer research to explore its potential in enhancing the effectiveness of cancer therapies by targeting DNA repair mechanisms. Its application may also extend to investigations of DNA damage response pathways and their implications in cancer biology. -
RAD51 Inhibitor
RAD51-IN-5 is a selective inhibitor of RAD51, a key protein involved in homologous recombination repair of DNA double-strand breaks. This compound demonstrates potential in exploring therapeutic strategies for conditions associated with mitochondrial defects. Its activity against RAD51 may provide insights into DNA repair mechanisms and related cellular processes in various research applications. -
RAD51 Inhibitor
RAD51-IN-3 is a potent inhibitor of the RAD51 protein, which plays a crucial role in homologous recombination and DNA repair mechanisms. By targeting RAD51, this compound interferes with DNA damage response pathways, making it valuable for research in cancer biology, particularly in exploring therapeutic strategies that exploit DNA repair deficiencies. Its application extends to studies investigating the sensitivity of tumor cells to chemotherapeutic agents and the development of novel cancer treatment modalities. -
RAD51 Inhibitor
RAD51-IN-4 is a potent inhibitor of the RAD51 protein, essential for homologous recombination and DNA repair in eukaryotic cells. This compound demonstrates significant anti-proliferative activity and has potential applications in studying conditions associated with mitochondrial defects and genomic stability. Researchers may utilize RAD51-IN-4 to explore cancer biology, therapeutic resistance, and the underlying mechanisms of DNA repair processes. -
RAD51 Inhibitor
RAD51-IN-7 is a selective inhibitor of RAD51, a key protein involved in homologous recombination and DNA repair mechanisms in eukaryotic cells. This compound is valuable for investigating conditions associated with mitochondrial dysfunction and its role in cancer biology. The potential applications of RAD51-IN-7 extend to studies targeting cellular responses to genotoxic stress and the development of therapeutic strategies for genetic diseases. -
RAD51 Inhibitor
RAD51-IN-6 is a highly effective inhibitor of RAD51, a key protein involved in homologous recombination and DNA repair in eukaryotic cells. This compound demonstrates significant biological activity by interfering with RAD51-mediated processes, making it a valuable tool for studying conditions related to mitochondrial defects and other genomic instability disorders. Its application in research may provide insights into therapeutic strategies targeting RAD51-related pathways. -
RAD51/HR Inhibitor
RI(dl)-2 is a potent inhibitor of RAD51, specifically targeting its D-loop activity with an IC50 of 11.1 µM, and effectively inhibiting homologous recombination (HR) with an IC50 of 3.0 µM. This compound disrupts HR-mediated repair of DNA double-strand breaks, leading to increased sensitivity in various cancer cell lines. RI(dl)-2 serves as a valuable tool for investigating HR processes and exploring potential therapeutic strategies in cancer research. -
RAD51 Inhibitor
DIDS is a RAD51 inhibitor that disrupts RAD51-mediated homologous pairing and strand exchange reactions, thereby impacting DNA repair processes. In addition to its primary function, DIDS also inhibits ABCA1 and VDAC1, affecting anion exchange and binding to red blood cell membranes. Furthermore, it has been shown to inhibit the activation of caspase-3 and -9, making it a valuable tool for cancer research applications. -
RAD51 Inhibitor
RAD51-IN-9 is a potent inhibitor of RAD51, effectively disrupting the binding of RAD51 to single-stranded DNA with an IC50 of 17.85 μM. This compound demonstrates an LD50 against HEK293 cells of 40.21 μM and is capable of sensitizing cells to the cytotoxic effects of Mitomycin C. RAD51-IN-9 is a valuable tool for research focused on DNA repair mechanisms and the therapeutic targeting of cancer cells. -
BRCA2-RAD51 Inhibitor
BRCA2-RAD51-IN-1 is a specific inhibitor of the BRCA2-RAD51 complex, demonstrated to have an EC50 value of 28 μM. This compound exhibits notable antitumor activity, making it a valuable tool for research into cancer treatments targeting DNA repair mechanisms. Its application in studies of BRCA-mediated tumorigenesis helps elucidate potential therapeutic strategies for cancers associated with BRCA2 mutations. -
PKMYT1 Inhibitor
Lunresertib (RP-6306) is a potent and selective inhibitor of PKMYT1, demonstrating an IC50 of 14 nM. This compound exhibits high selectivity for PKMYT1 in cellular binding assays, making it an effective tool for studying the role of this kinase in cancer biology. Lunresertib's anticancer properties highlight its potential applications in cancer research and therapeutic development. -
Wee1 Inhibitor
Azenosertib is a highly selective orally active Wee1 inhibitor, with an IC50 of 3.9 nM. It demonstrates significant antitumor activity, making it a valuable tool for cancer research. Azenosertib is utilized in studies investigating cell cycle regulation and DNA damage response pathways, contributing to the development of novel therapeutic strategies against various malignancies. -
WEE1 Inhibitor
WEE1-IN-14 is a selective WEE1 inhibitor, exhibiting an IC50 of 0.5 nM in L-RB-FEP calculations and 1.0 nM in the ADP-Glo kinase assay. By inhibiting WEE1, this compound disrupts the G2-M checkpoint in cancer cells, effectively removing cell cycle regulatory controls. The resulting early onset of mitotic failure triggers apoptosis in tumor cells, making WEE1-IN-14 a valuable reagent for research in cancer biology and therapeutic development. -
PKMYT1 Inhibitor
GSK-1520489A is a selective inhibitor of PKMYT1, an active protein kinase involved in cell cycle regulation. It exhibits an IC50 of 115 nM and a Ki value of 10.94 nM, demonstrating significant potency in inhibition. This compound is useful for exploring the role of PKMYT1 in tumorigenesis and cell proliferation, making it a valuable tool in cancer research and therapeutic discovery. -
Wee1 Kinase Inhibitor
WEE1-IN-4 is a potent inhibitor of the Wee1 kinase, exhibiting an IC50 of 0.011 μM. By targeting and inhibiting Wee1, this compound effectively abrogates the G2/M checkpoint, thereby promoting cell cycle progression in cancer cells. WEE1-IN-4 serves as a valuable tool for research in cancer biology and therapeutics, particularly in studies focused on cell cycle regulation and the development of combination therapies. -
Myt1 Inhibitor
(Rac)-lunresertib is a potent inhibitor of the membrane-associated tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1), with an IC50 of less than 10 nM. This compound demonstrates significant anticancer activity, making it a valuable reagent for research focused on targeting cell cycle regulation and kinase activity in cancer biology. Its precise inhibition of Myt1 positions it as a key tool for investigating therapeutic strategies in oncology. -
Wee1/2 Inhibitor
Bosutinib isomer is a potent inhibitor of the cell cycle regulators Wee1 and Wee2, exhibiting high binding affinities with Kd values of 43.7 ± 10.0 nM and 4.7 ± 2.3 nM, respectively. This compound is utilized in research applications aimed at understanding cell cycle modulation and exploring therapeutic strategies in cancer treatment, particularly in tumors with aberrant cell cycle regulation. -
Wee1 Inhibitor
WEE1-IN-3 is a potent inhibitor of Wee1 kinase, demonstrating an IC50 of less than 10 nM. This compound exhibits significant anticancer activity, making it a valuable tool for research in cancer biology. Its ability to modulate cell cycle regulation positions WEE1-IN-3 as a useful reagent for exploring therapeutic strategies against various cancer types. -
PKMYT1 Inhibitor
PKMYT1-IN-8 is a specific inhibitor of PKMYT1, demonstrating an IC50 of 9 nM. In addition to its primary target, it also inhibits several receptor tyrosine kinases, including EPHB3, EPHA1, KIT, EPHB1, EPHA2, EPHA3, and EPHB2, with varying IC50 values ranging from 1.79 to 10.9 μM. This compound effectively reduces the proliferation of the OVCAR3 cancer cell line, exhibiting a GI50 of 2.02 μM. PKMYT1-IN-8 is useful for research focused on cancer biology and targeted therapies. -
WEE1 Inhibitor
WEE1-IN-10 is a selective inhibitor of WEE1 kinase, a critical regulator of the cell cycle. It demonstrates potent inhibitory activity against LOVO cancer cell growth, with an IC50 of 0.524 μM. This compound is applicable in research focusing on diseases associated with aberrant WEE1 activity, providing insights into cell cycle regulation and potential therapeutic strategies. -
myt1 Inhibitor
(R)-lunresertib is a selective inhibitor of the myt1 kinase (PKMYT1), exhibiting an IC50 of 1360 nM. This compound is valuable for investigating Myt1-mediated signaling pathways and related oncogenic processes. Its application in cancer research highlights the potential for therapeutic interventions targeting Myt1 activity in tumor biology. -
Myt1 Inhibitor
Myt1-IN-3 is a potent inhibitor of Myt1, a membrane-associated kinase that specifically targets tyrosine and threonine residues and inhibits cdc2 activity. With an IC50 of less than 10 nM, it effectively modulates Myt1 activity, making it a valuable tool for investigating cell cycle regulation. This compound is suitable for research applications focused on cancer biology, cell proliferation, and kinase signaling pathways. -
Myt1 Inhibitor
Myt1-IN-1 is a potent inhibitor of Myt1 (PKMYT1), a membrane-associated kinase that specifically targets tyrosine and threonine residues with an IC50 of less than 10 nM. This compound exhibits significant anticancer activity, making it a valuable tool for research focused on cell cycle regulation and cancer therapeutics. Myt1-IN-1 is useful for studies investigating the role of Myt1 in tumor progression and offers insights into potential treatment strategies for various cancers. -
WEE1/PKMYT1 Inhibitor
WEE1/PKMYT1-IN-1 is a potent inhibitor targeting WEE1 and PKMYT1 kinases. This compound exhibits significant antiproliferative activity, making it suitable for research applications in cancer biology. It can be utilized to investigate cell cycle regulation and the mechanistic pathways involved in tumor cell proliferation. -
PKMYT1 Inhibitor
PKMYT1-IN-1 is a selective inhibitor of the membrane-associated tyrosine and threonine kinase, PKMYT1, demonstrating an IC50 of 8.8 nM. This reagent effectively inhibits the proliferation of HCC1569 tumor cells with an IC50 of 42 nM, making it a valuable tool for research into cancer biology and therapeutic interventions targeting PKMYT1 pathways. Its specificity and potency offer significant potential for studying the role of PKMYT1 in oncogenic processes. -
Myt1 Inhibitor
Myt1-IN-2 is a potent inhibitor of the membrane-associated cdc2-inhibitory kinase, Myt1 (Gene name: PKMYT1), demonstrating an IC50 of less than 10 nM. This compound exhibits significant antitumor activity, making it a valuable tool for cancer research. Myt1-IN-2 can be utilized in studies aimed at elucidating the role of Myt1 in cell cycle regulation and its implications in oncogenesis. -
PKMYT1 Inhibitor
PKMYT1-IN-9 is a selective inhibitor of PKMYT1, demonstrating an IC50 of 4.4 nM. This compound shows significantly higher selectivity for PKMYT1 compared to WEE1, which has an IC50 of 32.4 μM. PKMYT1-IN-9 has been characterized by its antitumor activity, making it a valuable tool in cancer research and therapeutic studies targeting checkpoint pathways. -
Wee1 Inhibitor
WEE1-IN-12 is a potent Wee1 kinase inhibitor with an IC50 of 2.0 nM. It demonstrates significant antiproliferative effects in HT29 colorectal cancer cells, exhibiting an IC50 of 1.07 μM. The compound enhances the efficacy of Gemcitabine, showing improved activity with an IC50 of 0.34 μM in combination studies. WEE1-IN-12 is valuable for research into targeted therapies for tumors, particularly colon cancer. -
PKMYT1 Inhibitor
PKMYT1-IN-2 is a potent inhibitor of PKMYT1, exhibiting an IC50 value of 5.7 nM. This compound effectively suppresses the growth of HCC1569 cancer cells with an IC50 of 22 nM. PKMYT1-IN-2 serves as a valuable tool for research in cancer biology, particularly in studies focused on targeting the PKMYT1 pathway for therapeutic interventions. -
WEE1/PKMYT1 Inhibitor
WEE1/PKMYT1-IN-2 is a potent inhibitor of WEE1 and PKMYT1 kinases, exhibiting an axial chiral P configuration. This compound demonstrates significant antiproliferative activity, making it a valuable tool for cancer research. It is particularly relevant for studies investigating cell cycle regulation and the therapeutic potential of targeting WEE1 and PKMYT1 in various malignancies. -
Wee1 Inhibitor
WEE1-IN-9 is a selective inhibitor of the Wee1 kinase, which plays a critical role in regulating the cell cycle by inhibiting the progression from G2 to mitosis. This compound exhibits potent anti-tumor activity and is valuable for studying the effects of Wee1 inhibition in cancer research. WEE1-IN-9 can be utilized in investigations of cancer cell proliferation and therapy resistance mechanisms, contributing to the development of novel cancer treatments. -
WEE1 Inhibitor
WEE1-IN-6 is a potent WEE1 inhibitor with a DC50 value of ≤ 100 nM. This compound effectively inhibits cell proliferation, making it a valuable tool for studies related to cell cycle regulation and cancer research. Its oral bioactivity enables convenient administration in various in vivo studies targeting WEE1 pathways. -
WEE1/PKMYT1 Inhibitor
WEE1/PKMYT1-IN-3 is a potent inhibitor of WEE1 and PKMYT1, specifically designed with an axial chiral M configuration. This compound exhibits significant antiproliferative activity, making it a valuable tool for cancer research. It can be utilized to explore the mechanisms of cell cycle regulation and to investigate therapeutic strategies targeting these critical kinases in various malignancies. -
WEE1 Inhibitor
WEE1-IN-8 is a highly selective WEE1 inhibitor, exhibiting an IC50 of 0.98 nM. This compound is effective in research applications targeting various malignancies, including pancreatic cancer, ovarian cancer, colorectal cancer, and uterine serous carcinoma. By facilitating the abrogation of G2/M checkpoint control, WEE1-IN-8 demonstrates potential as a therapeutic agent in cancer treatment strategies. -
Wee1 Inhibitor
WEE1-IN-11 is a potent inhibitor of the Wee1 kinase, demonstrating an impressive IC50 of 2.0 nM against CDK2. This compound effectively inhibits various cancer cell lines, including NCI-H446, A427, OVCAR3, C33A, and WiDr, with IC50 values of 93.9 nM, 34.5 nM, 86.7 nM, 23.1 nM, and 85 nM, respectively. It serves as a valuable tool for investigating cell cycle regulation and the therapeutic potential of targeting Wee1 in cancer research. -
Wee1 Inhibitor
PKMYT1-IN-4 is a potent PKMYT1 inhibitor with an IC50 of less than 50 nM. This compound selectively targets the Wee1 kinase, a critical regulator of the cell cycle. PKMYT1-IN-4 is utilized in research applications focused on cell cycle regulation and cancer biology, making it suitable for studies exploring therapeutic strategies against proliferative diseases. -
MYT1 Kinase Inhibitor
Myt1-IN-6 is a selective inhibitor of MYT1 kinase, which plays a crucial role in the regulation of cell cycle progression and neuronal differentiation. This compound is particularly relevant for studies involving RB1-deficient cancers, such as triple-negative breast cancer, where MYT1 activity may contribute to oncogenesis and tumor progression. Myt1-IN-6 serves as a valuable tool for exploring therapeutic strategies targeting MYT1 in various malignancies. -
G-quadruplex Inhibitor
Phen-DC3 Trifluoromethanesulfonate is a specific ligand that targets G-quadruplex (G4) structures, effectively inhibiting the helicases FANCJ and DinG with IC50 values of 65±6 nM and 50±10 nM, respectively. This compound plays a critical role in research focused on telomere biology, DNA replication, and cancer therapeutics. Its ability to modulate G4 structures makes it a valuable tool for investigating G4-associated cellular processes and the development of novel anti-cancer strategies. -
LIMK Inhibitor
CRT0105950 is a potent LIMK inhibitor, selectively targeting LIMK1 and LIMK2 with IC50 values of 0.3 nM and 1 nM, respectively. Its primary mechanism involves the inhibition of LIM kinases, which play a crucial role in regulating actin cytoskeleton dynamics and cell motility. This reagent is valuable for investigating tumor biology and potential therapeutic pathways in cancer research. -
LIMK1 Inhibitor
SR7826 is a potent and selective LIMK1 inhibitor, exhibiting an IC50 of 43 nM. This bis-aryl urea derivative demonstrates over 100-fold selectivity for LIMK1 compared to ROCK and JNK kinases. SR7826 serves as a valuable tool for investigating LIMK1-related signaling pathways and its role in cellular processes such as cytoskeletal dynamics and cancer progression. -
LIMK1/2 Inhibitor
TH470 is a highly selective inhibitor of LIMK1 and LIMK2, exhibiting IC50 values of 9.8 nM and 13 nM, respectively. This compound effectively modulates the actin cytoskeleton and related cellular processes by inhibiting LIM kinase activity. TH470 is particularly valuable in the study of orphan diseases and other conditions related to dysregulated LIMK signaling. -
LIMK Inhibitor
LIMK1 inhibitor BMS-4 is a selective inhibitor of LIM Kinases (LIMK1 and LIMK2). By inhibiting LIMK1, BMS-4 effectively blocks the phosphorylation of cofilin, a critical substrate, thereby modulating actin dynamics. It has demonstrated noncytotoxicity in A549 cells, making it a valuable tool for investigating LIMK-related pathways and their roles in cancer cell migration and invasion. -
LIM Kinase (LIMK) Inhibitor
MDI-114215 is an allosteric inhibitor targeting LIM Kinase 1 and 2 (LIMK1/2). It effectively inhibits the phosphorylation of cofilin in induced pluripotent stem cells (iPSCs) derived from mouse brain regions. This compound shows potential applications in research related to Fragile X Syndrome (FXS), enabling investigations into cellular pathways affected by LIMK activity. -
LIMK1 Inhibitor
LIMK1 inhibitor 2 is a selective inhibitor of LIM kinase 1 (LIMK1), demonstrating an IC50 value of 9 μM. This compound effectively blocks LIMK1 activity, leading to the modulation of cytoskeletal dynamics. It is primarily utilized in research to investigate cellular processes such as cell migration, proliferation, and differentiation, contributing valuable insights into cancer biology and other related fields. -
LIMK1 Inhibitor
8β,9α-Dihydroxylindan-4(5),7(11)-dien-8alpha,12-olide is a sesquiterpene that acts as a selective inhibitor of LIMK1. By targeting this kinase, the compound effectively modulates cell motility, making it valuable for studies investigating cytoskeletal dynamics and cell migration. This reagent is applicable in various research contexts, including cancer metastasis and neurobiology, where LIMK1 plays a critical role. -
LIMK2 Inhibitor
LIMK-IN-3 is a potent inhibitor of LIMK2, demonstrating an IC50 of 1.2 nM. This compound exhibits significant inhibition of LIMK2 activity, which is crucial for understanding the role of LIMK2 in various cellular processes. LIMK-IN-3 is particularly relevant in glaucoma research, providing valuable insights into the molecular mechanisms underlying this condition. -
LIMK Inhibitor
LIJTF500025 is a potent and selective LIMK inhibitor that targets LIMK1 and LIMK2, exhibiting pIC50 values of 6.77 and 7.03, respectively, as determined by NanoBRET. This compound plays a crucial role in modulating actin dynamics and has potential applications in cancer research. Its ability to inhibit LIM kinase activity makes it a valuable tool for investigating the mechanisms underlying tumor progression and metastasis.
